Search


Jefferies London 2026: Nuvation Bio Founder & CEO David Hung shares an update on the launch of IBTROZI (next-gen ROS1 inhibitor and follow-on pipeline projects
He discusses the launch and his thoughts on any future copetitors in the space. Plus an update on the mIDH1 inhibitor safusidenib, and a drug-drug interaction platform that was the basis for founding the company. Coverage brought to you by
3 hours ago


Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio
He discusses the clinical profile of IBTROZI, how the launch is going, and describes other work the company is doing in precision...
Oct 8, 2025


Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June
He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates,...
Apr 9, 2025






.png)
